Axumin Detects 68% of Recurrent Prostate Cancer in Phase III Study

Data validates multimodal AI biomarker’s ability to help inform treatment decisions omCSPC

New data validated a multimodal artificial intelligence-based biomarker’s ability to help inform treatment decisions for patients with oligometastatic castration-sensitive prostate cancer, including metastasis-directed therapy benefit.

October 04, 2024

Vol.50 No.37

Drugs & Targets

Bayer submits sNDA to FDA for expanded indication for Nubeqa for treatment of mHSPC

Bayer announced the submission of a supplemental new drug application to FDA for the oral androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate cancer.

September 27, 2024

Vol.50 No.36

Clinical Roundup

NIH study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry

West African genetic ancestry was associated with increased prostate cancer among men living in disadvantaged neighborhoods but not among men living in more affluent neighborhoods, according to a new study led by NIH researchers. The findings suggest that neighborhood environment may play a role in determining how genetic ancestry influences prostate cancer risk.

September 20, 2024

Vol.50 No.35

Clinical Roundup

New AI model can prevent unnecessary prostate removals

A research team at MedUni Vienna developed a method which utilizes multi-omics and machine learning to identify prostate cancer patients for whom surgical treatment is the best option, potentially avoiding unnecessary surgery in patients with a lower risk of tumor spread.

September 13, 2024

Vol.50 No.34

Clinical Roundup

Study confirms AI outperforms conventional methods for prostate cancer ECE

A study recently published in BJUI Compass found that Unfold AI, an FDA-cleared artificial intelligence algorithm developed by Avenda Health, accurately predicted extracapsular extension risk (ECE) and outperformed conventional methodologies.

September 06, 2024

Vol.50 No.33

Clinical Roundup

Updated ArteraAI Prostate Test informs active surveillance decisions for lower-risk prostate cancer

Artera, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced an update to the ArteraAI Prostate Test, enabling clinicians to make more informed decisions about active surveillance when delivering care to prostate cancer patients.

August 09, 2024

Vol.50 No.32

Axumin Detects 68% of Recurrent Prostate Cancer in Phase III Study

YOU MAY BE INTERESTED IN

Data validates multimodal AI biomarker’s ability to help inform treatment decisions omCSPC

Bayer submits sNDA to FDA for expanded indication for Nubeqa for treatment of mHSPC

NIH study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry

New AI model can prevent unnecessary prostate removals

Study confirms AI outperforms conventional methods for prostate cancer ECE

Updated ArteraAI Prostate Test informs active surveillance decisions for lower-risk prostate cancer

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login